Tutorial on Monoclonal Antibody Pharmacokinetics and Its Considerations in Early Development

The tutorial introduces the readers to the fundamentals of antibody pharmacokinetics (PK) in the context of drug development. Topics covered include an overview of antibody development, PK characteristics, and the application of antibody PK/pharmacodynamics (PD) in research and development decision‐...

Descripción completa

Detalles Bibliográficos
Autores principales: Ovacik, Meric, Lin, Kedan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Tutorial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6226118/
https://www.ncbi.nlm.nih.gov/pubmed/29877608
http://dx.doi.org/10.1111/cts.12567
_version_ 1783369901271941120
author Ovacik, Meric
Lin, Kedan
author_facet Ovacik, Meric
Lin, Kedan
author_sort Ovacik, Meric
collection PubMed
description The tutorial introduces the readers to the fundamentals of antibody pharmacokinetics (PK) in the context of drug development. Topics covered include an overview of antibody development, PK characteristics, and the application of antibody PK/pharmacodynamics (PD) in research and development decision‐making. We also discuss the general considerations for planning a nonclinical PK program and describe the types of PK studies that should be performed during early development of monoclonal antibodies.
format Online
Article
Text
id pubmed-6226118
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-62261182018-11-19 Tutorial on Monoclonal Antibody Pharmacokinetics and Its Considerations in Early Development Ovacik, Meric Lin, Kedan Clin Transl Sci Tutorial The tutorial introduces the readers to the fundamentals of antibody pharmacokinetics (PK) in the context of drug development. Topics covered include an overview of antibody development, PK characteristics, and the application of antibody PK/pharmacodynamics (PD) in research and development decision‐making. We also discuss the general considerations for planning a nonclinical PK program and describe the types of PK studies that should be performed during early development of monoclonal antibodies. John Wiley and Sons Inc. 2018-08-07 2018-11 /pmc/articles/PMC6226118/ /pubmed/29877608 http://dx.doi.org/10.1111/cts.12567 Text en © 2018 The Authors. Clinical and Translational Science published by Wiley Periodicals, Inc. on behalf of American Society for Clinical Pharmacology and Therapeutics This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Tutorial
Ovacik, Meric
Lin, Kedan
Tutorial on Monoclonal Antibody Pharmacokinetics and Its Considerations in Early Development
title Tutorial on Monoclonal Antibody Pharmacokinetics and Its Considerations in Early Development
title_full Tutorial on Monoclonal Antibody Pharmacokinetics and Its Considerations in Early Development
title_fullStr Tutorial on Monoclonal Antibody Pharmacokinetics and Its Considerations in Early Development
title_full_unstemmed Tutorial on Monoclonal Antibody Pharmacokinetics and Its Considerations in Early Development
title_short Tutorial on Monoclonal Antibody Pharmacokinetics and Its Considerations in Early Development
title_sort tutorial on monoclonal antibody pharmacokinetics and its considerations in early development
topic Tutorial
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6226118/
https://www.ncbi.nlm.nih.gov/pubmed/29877608
http://dx.doi.org/10.1111/cts.12567
work_keys_str_mv AT ovacikmeric tutorialonmonoclonalantibodypharmacokineticsanditsconsiderationsinearlydevelopment
AT linkedan tutorialonmonoclonalantibodypharmacokineticsanditsconsiderationsinearlydevelopment

Ejemplares similares